Journal
LEUKEMIA
Volume 23, Issue 11, Pages 1957-1963Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2009.168
Keywords
BCR-ABL; chronic myeloid leukemia; molecular monitoring; international scale; conversion factor; EUTOS for CML
Categories
Funding
- European LeukemiaNet
- European Union,
- Sixth Framework Programme [LSHC-CT-2004-503216]
- Novartis Pharmaceuticals as part of the EUTOS for CML collaboration
- German Jose-Carreras-Foundation [H 03/01]
Ask authors/readers for more resources
The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has shown prognostic impact with regard to progression-free survival. Until recently, variations in methods used to quantify BCR-ABL made it difficult to compare results between laboratories. An international program is now underway to harmonize the reporting of results according to an international scale (IS). In this review, we consider the background to the IS and the progress that has been made to date, with a particular focus on ongoing harmonization efforts in Europe. We provide recommendations for the propagation of the IS by national or regional laboratory networks. Leukemia (2009) 23, 1957-1963; doi:10.1038/leu.2009.168; published online 27 August 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available